TABLE 2.
Some clinical information regarding the patients and the dates that SARS‐CoV‐2 RT‐PCRs were tested positive
| P. | Gender/age | Reason for transplant | Time of transplant | Time elapsed between transplant to COVID19 PCR positivity | Lung imaging findings | Treatment | Immunosuppressive Treatment |
|---|---|---|---|---|---|---|---|
| 1 | M/47 | HBV | October 2019 | (2 Times) 229 d after/329 d after | Vascular dilatation/bronchial changes |
HQ FAV |
TACR‐Eve |
| 2 | M/51 | PSC | February 2020 | 185 d after | Ground‐glass opacity | FAV | TACR |
| 3 | M/45 | AH | February 2020 | 179 d after | Fibrotic changes | — | TACR |
| 4 | M/35 | CR | February 2020 | 191 d after | Ground glass opacity/interlobular septal thickening | FAV | TACR‐Eve |
| 5 | M/57 |
HBV+ HCC |
March 2020 | 133 d after | Ground‐glass opacity | FAV | TACR |
| 6 | M/40 | HBV | April 2020 | 139 d after | Ground‐glass opacity | FAV | TACR |
| 7 | M/64 |
HBV+ HCC |
April 2020 | 148 d after | Ground‐glass opacity | FAV | TACR‐Eve |
| 8 | M/54 | AH | April 2020 | 144 d after | Parenchymal band and accompanying subsegmental atelectasis | — | TACR‐Eve |
| 9 | F/43 | PBS | June 2020 | Detected preoperatively | Parenchymal lower lobe basal fibrotic bands and areas of linear atelectasis | FAV | TACR |
Abbreviations: AH, autoimmune hepatitis; CR, chronic rejection; Eve, everolimus; F, female; FAV, favipiravir; HBV, hepatitis B infection; HCC, hepatitis C infection; HQ, hydroxychloroquine; M, male; P, patient; PBS, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; TACR, tacrolimus.